Invokana Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to AACE Conference on SGLT2 Inhibitor Diabetes Drugs, Diabetic Ketoacidosis

October 12, 2015 - The Invokana lawsuit (http://www.invokanalawsuitcenter.com/) attorneys at Bernstein Liebhard LLP note that the American Association of Clinical Endocrinologists (AACE) is scheduled to convene a conference later this month to review data regarding the potential link between a class of Type 2 diabetes drugs called SGLT2 inhibitor and the development of diabetic ketoacidosis. The conference was announced after the U.S. Food & Drug Administration (FDA) disclosed it had identified 20 cases of this dangerous condition in patients treated with SGLT2 inhibitors from March 2013 to June 6, 2014. According to a statement from the AACE, the upcoming conference is intended to "provide answers to questions from its membership raised in response to recent case reports and publications on the subject."

"Since the FDA announced in May that it was reviewing the potential association between SGLT2 inhibitors and diabetic ketoacidosis, our Firm has heard from a number of Type 2 diabetes patients who were allegedly diagnosed with this life-threatening condition while using Invokana and other drugs in this class. We are pleased that the AACE has decided to investigate this matter," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating legal claims on behalf of Type 2 diabetes patients who were hospitalized following a diagnosis of diabetic ketoacidosis, acidosis, ketoacidosis, or ketosis, allegedly due to their use of SGLT2 inhibitors.

SGLT2 Inhibitors and Diabetic Ketoacidosis
Invokana was approved by the FDA in March 2013, and was the first SGLT2 inhibitor marketed in the U.S. for the treatment of Type 2 diabetes. A number of other SGLT2 inhibitors have since been cleared for sale by the agency, including:

Invokamet

Farxiga

Xigduo XR

Jardiance

Glyxambi

All of the above medications work to lower blood sugar levels by facilitating the removal of glucose through the urine. SGLT2 inhibitors have only been approved to treat Type 2 diabetes, and they are not indicated for use in Type 1 diabetics.

The FDA announced that it was reviewing SGLT2 inhibitors and diabetic ketoacidosis on May 15th, and is currently working to determine whether changes are needed in the prescribing information for this class of medications. Ketoacidosis, which has the potential to cause diabetic coma or death, occurs when the body produces excessive amounts of blood acids called ketones. All of the cases reported to the FDA resulted in the need for emergency medical treatment and/or hospitalization. The agency has advised SGLT2 inhibitor patients to seek medical attention immediately if they experience difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness.

Individuals who were allegedly hospitalized with diabetic ketoacidosis due to their use of Invokana or another SGLT2 inhibitor may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. To find out more about available legal options, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.invokanalawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author